Breaking News

CereMark, SpectronRX Enter Clinical Supply Pact

SpectronRx will manufacture [F-18] Flornaptitril for CereMark's Phase 3 trial using the patented radiochemical synthetic technique.

CereMark Pharma LLC entered into a supply agreement with SpectronRx for the production of [F-18] Flornaptitril, an investigational new positron emission tomography (PET) imaging radiopharmaceutical being studied in the management of neurodegenerative diseases including the development and progression of Alzheimer’s Disease (AD), Chronic Traumatic Encephalopathy (CTE), and other diseases associated with cognitive impairment.  CereMark’s CEO Henry Chilton said, “We are pleased to be working wit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters